Introduction
In 2001, Hamano et al. [1] described a new clinical entity called IgG4-related pancreatitis. Soon afterwards, this was recognized to be a systemic disease and was renamed 'IgG4-related disease'. It usually presents as a mass lesion in the pancreas, hepatobiliary tract, orbit and adnexa, lymph nodes, gastrointestinal tract, retroperitoneum and salivary gland amongst other reported sites. An excisional biopsy was performed, and the pathology revealed ulcerated conjunctiva with fibrosis, numerous plasma cells and 101 IgG4-positive plasma cells in the most affected high-power field (HPF). The IgG4:IgG ratio was 28% (101/361; fig. 1 b-d) . Based on the clinical examination and pathology report, the patient was diagnosed with conjunctival inflammation suggestive of IgG4-related disease. Systemic workup by a rheumatologist, including CMP, urinalysis, ESR (4 mm/h, reference range 0-15), CRP (0.1 mg/dl, reference range 0-1.0), TSH (0.764 μU/ml, reference range 0.4-5.5), ANCA (negative), and syphilis IgG (<0.2 AI, reference range <0.9), was within normal limits, excluding obvious underlying systemic disease. In addition, CT scan of the chest and MRI of the orbit were within normal limits. The patient was started on oral prednisone (40 mg) and was slowly tapered down over the next 6 weeks. On 18 months of follow-up, the patient continues to be symptom free without evidence of systemic disease or ocular recurrence.
Discussion
Our case describes an isolated conjunctival lesion suggestive of IgG4-related disease in the absence of associated orbital inflammation. While the lacrimal gland is the most common ophthalmic manifestation in IgG4-related disease, the conjunctiva was initially believed to be spared [4] . Recent case reports have shown conjunctival involvement in IgG4-related disease with adnexal involvement [6, 8] or in isolation [7] .
The diagnostic criteria for IgG4-related disease are constantly evolving, as our understanding of this newly described entity is growing. Umehara et al. [9] outlined comprehensive diagnostic criteria for IgG4-related disease that included (1) clinical inflammatory lesion, (2) elevated serum IgG4 levels, and (3) histopathological features consistent with IgG4-related disease ( table 1 ). They concluded that, if all three criteria are present, then a definite diagnosis of IgG4-related disease could be made. Since serum IgG4 levels can be normal in up to 40% of patients with IgG4-related disease [10] , histopathological features are essential in establishing the diagnosis, and 53 they include dense lymphocytic infiltrate, fibrosis (at least focally storiform) and obliterative phlebitis [11] . Moreover, a consensus pathology paper showed that histopathological features and clinicopathological correlation are more important for the diagnosis of IgG4-related disease than the suggested cutoffs of >10 IgG4 plasma cells/ HPF and an IgG4:IgG ratio of >40% [12] . Our patient presented with an isolated inflammatory conjunctival lesion associated with fibrosis (not storiform) and an increase in IgG4 plasma cells (101 cells/ HPF) on pathology. Her serum IgG4 level was not measured prior to treatment and, on pathology, the IgG4:IgG ratio was 28% (<40%) with no clear evidence of phlebitis. The constellation of these findings was suggestive of IgG4-related disease in the absence of systemic or orbital manifestations. Matsuo et al. [13] reported a higher incidence of systemic manifestations when IgG4 involved the ocular adnexa. Thus, the patient continues to be closely monitored for local and systemic recurrence.
Conjunctival inflammation of unknown cause should be considered within the spectrum of ocular and adnexal manifestations of IgG4-related disease. Because of its systemic implications, ophthalmologists should be aware of this diagnosis that could be easily overlooked as idiopathic inflammation.
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